41 related articles for article (PubMed ID: 11488934)
21. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Zhang W; Ohnishi K; Shigeno K; Fujisawa S; Naito K; Nakamura S; Takeshita K; Takeshita A; Ohno R
Leukemia; 1998 Sep; 12(9):1383-91. PubMed ID: 9737686
[TBL] [Abstract][Full Text] [Related]
22. Catalase activity and arsenic sensitivity in acute leukemia.
Coe E; Schimmer AD
Leuk Lymphoma; 2008 Oct; 49(10):1976-81. PubMed ID: 18949620
[TBL] [Abstract][Full Text] [Related]
23. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
[TBL] [Abstract][Full Text] [Related]
24. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
[TBL] [Abstract][Full Text] [Related]
25. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Lu M; Levin J; Sulpice E; Sequeira-Le Grand A; Alemany M; Caen JP; Han ZC
Exp Hematol; 1999 May; 27(5):845-52. PubMed ID: 10340400
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide: acute promyelocytic leukemia and beyond.
Bachleitner-Hofmann T; Kees M; Gisslinger H
Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
[TBL] [Abstract][Full Text] [Related]
27. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Evens AM; Tallman MS; Gartenhaus RB
Leuk Res; 2004 Sep; 28(9):891-900. PubMed ID: 15234563
[TBL] [Abstract][Full Text] [Related]
28. Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells.
Bruserud Ø; Glenjen N; Gjertsen BT; Herfindal L; Døskeland SO
Expert Opin Biol Ther; 2002 Feb; 2(2):197-210. PubMed ID: 11849119
[TBL] [Abstract][Full Text] [Related]
29. Targeting leukemic stem cells by breaking their dormancy.
Essers MA; Trumpp A
Mol Oncol; 2010 Oct; 4(5):443-50. PubMed ID: 20599449
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of drug resistance in AML.
Andreeff M; Konopleva M
Cancer Treat Res; 2002; 112():237-62. PubMed ID: 12481719
[No Abstract] [Full Text] [Related]
31. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
Fei W; Li C; Tao J; Cai X; Yao W; Ye Y; Zhang Y; Yao Y; Song Q; Li F; Zheng C
Int J Pharm; 2020 Jun; 583():119385. PubMed ID: 32376447
[TBL] [Abstract][Full Text] [Related]
32. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
34. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Alemany M; Levin J
Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
